Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack patients may ditch aspirin sooner with new stent

NCT ID NCT05785897

Disease control Sponsor: IGLESIAS Juan Fernando Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug-coated stent and a blood thinner strategy without aspirin for people who have had a severe heart attack. The goal is to see if this approach lowers the risk of serious bleeding while still preventing future heart attacks, strokes, or the need for another procedure. About 350 participants will be randomly assigned to either the new stent plus a single blood thinner, or the standard stent plus two blood thinners (including aspirin) for 6-12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sirolimus-based nanocarrier eluting stent and P2Y12 inhibitor (ticagrelor or prasugrel) without aspirin
What this could lead to
If successful, this could offer a safer treatment option after a heart attack, reducing bleeding risk while still preventing future heart problems.
What could go wrong
This is a mid-sized trial, and the new approach may not be as effective at preventing stent clotting or heart attacks as the standard dual therapy. Bleeding risks, though potentially lower, still exist.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age ≥18 years. * Subjects who have received DAPT consisting of aspirin and any of the commercially available P2Y12 receptor inhibitors (ticagrelor, prasugrel, or clopidogrel) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI. * Subjects with ≥1 acute infarct artery target vessel with ≥1 coronary artery stenosis in a native coronary artery with diameter from 2.25 to 4.0 mm who underwent successful primary PCI, defined as primary PCI with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation, and final residual stenosis \<30% by visual estimation or 20% by quantitative coronary angiography (QCA) \[38\]. * Subject willing to participate and able to understand, read and sign the informed consent form. Exclusion criteria: * Known allergy or intolerance to aspirin, ticagrelor, prasugrel, or sirolimus. * Inability to adhere to DAPT for at least 6 months. * Patient already on DAPT at index presentation due to recent PCI for chronic coronary syndrome (\<6 months) or ACS (\<12 months). * Patient on chronic oral anticoagulation at index presentation. * Patient with mechanical complication of STEMI. * Patient with STEMI due to stent thrombosis. * Planned non-cardiac surgery that cannot be postponed for at least 6 months. * Participation or planned participation in another interventional clinical trial. * Life expectancy \<1 years. * Pregnancy. * Unwillingness or inability (e.g. physical or cognitive) to comply with study procedure, medication adherence and schedule.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST elevation myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST elevation myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Geneva University Hospitals

    RECRUITING

    Geneva, Canton of Geneva, 1205, Switzerland

  • Zurich University Hospital

    RECRUITING

    Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.